Skip to main content
Clinical Trials/NCT05238727
NCT05238727
Unknown
Not Applicable

Effect of Volume Increase Compared to Supplemental 4% Articaine Buccal Infiltration on Mepivacaine Inferior Alveolar Nerve Block Success in Cases With Symptomatic Irreversible Pulpitis: A Randomized Clinical Trial

Cairo University0 sites75 target enrollmentMarch 2022

Overview

Phase
Not Applicable
Intervention
1.8 ml mepivacaine hydrochloride
Conditions
Symptomatic Irreversible Pulpitis
Sponsor
Cairo University
Enrollment
75
Primary Endpoint
Anesthetic success
Last Updated
4 years ago

Overview

Brief Summary

To assess the anesthetic success of inferior alveolar nerve block (IANB), intraoperative pain intensity and need for supplemental anesthesia on administration of 1.8ml or 3.6ml 2% mepivacaine IANB, or 1.8ml 2% mepivacaine IANB plus 1.8ml 4% articaine buccal infiltration (BI) in mandibular molars with symptomatic irreversible pulpitis.

Detailed Description

Patients with moderate-to-severe preoperative pain related to mandibular molars with symptomatic irreversible pulpitis will be included. Patients receive 1.8 ml, 3.6 ml 2% mepivacaine IANB, or 1.8ml 2% mepivacaine IANB plus 1.8ml 4% articaine BI. Anesthetic success of inferior alveolar nerve block, intraoperative pain intensity and need for supplemental anesthesia will be assessed during treatment.

Registry
clinicaltrials.gov
Start Date
March 2022
End Date
September 2023
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Reham Anwar Mohammed El Said Sleem

Ms

Cairo University

Eligibility Criteria

Inclusion Criteria

  • Patients in good health (ASA Class I, II).
  • Age between 18-60 years old.
  • Males or females.
  • Mandibular molar teeth diagnosed with symptomatic irreversible pulpitis.
  • Patients who can understand NRS scale and sign the informed consent.

Exclusion Criteria

  • Patients who had used any type of analgesic medication during the preceding 8 hours before the treatment.
  • Pregnant or nursing females.
  • Patients with a contraindication for the use of mepivacaine, articaine or any used drug or material.

Arms & Interventions

1.8 ml mepivacaine IANB

Intervention: 1.8 ml mepivacaine hydrochloride

3.6 ml mepivacaine IANB

Intervention: 3.6 ml mepivacaine hydrochloride

1.8 ml mepivacaine IANB plus 1.8 ml articaine BI

Intervention: 1.8 ml mepivacaine hydrochloride IANB plus 1.8 ml articaine hydrochloride BI

Outcomes

Primary Outcomes

Anesthetic success

Time Frame: During the treatment

Will be recorded by 11-point numerical rating scale (NRS) consisting of numbers from 0 through 10. 0: reading represents "no pain" 1-3 : readings represent "mild pain" 4-6 : readings represent "moderate pain" 7-10 : readings represent "severe pain". Success will be defined as no to mild pain.

Secondary Outcomes

  • Intraoperative pain(During the treatment)
  • Need for supplemental anesthesia(During the treatment)

Similar Trials